Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy

Autor: Multicenter Uveitis Steroid Treatment (Must) Trial, Michael M. Altaweel, Douglas A. Jabs, David S. Friedman, Elizabeth A. Sugar, Mark L. Van Natta, Lyndell L Lim, Susan G. Elner, Janet T. Holbrook, Husam Ansari, James P. Dunn, John H. Kempen
Rok vydání: 2020
Předmět:
Zdroj: Am J Ophthalmol
ISSN: 0002-9394
Popis: PURPOSE: To evaluate long-term risk and outcomes of glaucoma in eyes with intermediate, posterior, and panuveitis managed with systemic or fluocinolone acetonide (0.59 mg, “implant”) therapy. DESIGN: Prospective Follow-up of the Multicenter Uveitis Steroid Treatment (MUST) Clinical Trial Cohort METHODS: Patients with intermediate, posterior or panuveitis randomized to implant or systemic therapy (corticosteroid plus immunosuppression in >90%) were followed prospectively for glaucoma incidence and outcome. RESULTS: Among 405 uveitic at-risk eyes of 232 patients (median follow-up=6.9 years), 40% (79/196) of eyes assigned and treated with implant and 8% (17/209) of eyes assigned and treated with systemic therapy (censoring eyes receiving an implant upon implantation) developed glaucoma (Hazard Ratio (HR)=5.9 (95% CI: 3.2, 10.8); p
Databáze: OpenAIRE